DNA修复基因XRCC1单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗后生存期的关系

目的 研究DNA修复基因XRCC1单核苷酸多态性与晚期非小细胞肺癌（NSCLC）患者对顺铂或卡铂为主的方案化疗后生存期的关系。方法 经病理学确诊的晚期NSCLC患者135例，采用顺铂或卡铂为主的方案进行化疗。化疗前采集患者外周血，以聚合酶链反应-限制性长度片段分析（PCR—RFLP）方法进行XRCC1 Arg194Trp和XRCC1 Arg399Gln基因多态性的分型。比较不同基因型患者化疗后的中位生存时间（MST）和1、2年生存率。结果 中位随访12个月，135例患者的MST和1、2年生存率分别为12个月和48．1％、13．1％。携带XRCC1 399Arg／Arg的NSCLC患者化疗后MST和1、2年生存率分别为14．0个月和56．3％、20．8％；携带XRCC1 399Arg／Gin或Gin／Gln基因型的NSCLC患者化疗后MST和1、2年生存率分别为10．0个月和39．0％、7．6％，差异均有显著性（P〈0．05）。携带XRCC1 194Arg／Arg的NSCLC患者的MST和1、2年生存率分别为11．0个月和43、6％、13．2％；携带XRCC1 194Arg／Gln或Gln／Gln基因型的NSCLC患者MST和1、2年生存率分别为13．0个月和49．6％、11．3％，两组之间差异无显著性（P〉0．05）。结论 XRCC1 Arg399Gln基因多态性与晚期NSCLC患者铂类药物化疗后的生存期有关。XRCC1 Arg3 99Gln基因多态性可以在一定程度上判断晚期NSCLC患者铂类药物化疗后的预后。

Polymorphisms of DNA X-ray repair cross complementary protein 1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer

Objective To investigate the relationship between genetic polymorphisms of DNA X-ray repair cross complementary protein 1(XRCC1)and survival of patients with advanced non-small cell lung cancer (NSCLC) treated with cisplatin or carboplatin based chemotherapy.Methods 135 patients with advanced NSCLC were treated with cisplatin or carboplatin-based chemotherapy.XRCC1 Arg 194 Trp and XRCC1 Arg 399 Gln were determined by PCR-RFLP methods.The median survival time (MST),survival rates of one and two years were obtained after chemotherapy in each group.Results Median follow-up period was 12 months.MST,1-year and 2-year survival rates of 135 patients were 12 months,48.1%,13.1%,respectively.MST,1-year survival and 2-year survival rates of patients with the 399Arg/Arg genotype were significantly higher than those of 399Arg/Gln or Gln/Gln genotype (14.0 months,56.3%,20.8% vs.10.0 months,39.0%,7.6% respectively),with significant difference (P<0.05).There was no difference of MST,1-year and 2-year survival rates in patients with 194 Arg/Arg genotype and 194 Arg/Gln or Gln/Gln genotype (11.0 months,43.6% and 13.2% vs.13.0 months,49.6% and 11.3%, P>0.05).Conclusion Polymorphisms of XRCC1 Arg 399 Gln might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy which might be a prognostic factor in platin-treated patients with advanced NSCLC.